Zai Lab shares up on Chinese regulatory approval for antibiotic

Paratek Pharmaceuticals

16/12/2021 11:34

** U.S.-listed shares of China-based drugmaker  ZLAB.O  up
~3.6% at $56.90 premarket
    ** China's health regulator has approved Zai Lab's drug,
Nuzyra, for treating community-acquired bacterial pneumonia and
acute bacterial skin and skin structure infections - co
 urn:newsml:reuters.com:*:nGNX4bJQ2Z 
    ** Nuzyra, available as both oral and intravenous
formulations, was approved as a Category 1 innovative drug by
the NMPA and is locally manufactured in China
    ** Nuzyra had been approved by the U.S. FDA for the same
indications and has been marketed in the United States since
2019 by partner Paratek Pharmaceuticals Inc  PRTK.O ; ZLAB
in-licensed the rights to the drug for the Greater China region
in 2017
    ** Up to Wednesday's close, stock had fallen 59.44% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))